SynthesisJournal of gastrointestinal cancer2026
Durable Survival Outcomes After Liver Transplantation for Colorectal Liver Metastases: A Systematic Review and Single-arm Meta-analysis of Prospective Clinical Trials.
Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver transplantation (LT) has emerged as a potential treatment option for selected patients with colorectal liver metastases (CRLM), but existing meta-analyses are limited by heterogeneous populations and mixed treatment modalities.
methodsA systematic review and single-arm meta-analysis were conducted in accordance with PRISMA guidelines. Studies reporting outcomes following LT for CRLM were included. Primary outcomes were overall survival (OS) and progression-free survival (PFS) at predefined time points. Secondary outcomes included adverse events. Pooled proportions were calculated using random-effects models with logit transformation and Hartung-Knapp adjustment. Heterogeneity was assessed using the I² statistic.
resultsFour prospective studies (1 RCT, 3 prospective cohorts) comprising 118 patients were included. Studies were conducted in Norway (SECA-I, n = 21; SECA-II, n = 15), the United Kingdom (n = 50), and a European multicentre RCT (TransMet, n = 32). Median age ranged from 55 to 58 years; all patients had liver-only metastases with resected primary tumors and had received pre-transplant chemotherapy. The pooled 3-year OS was 69% (95% CI, 52-82%; I² = 0.0%), and the pooled 5-year OS was 62% (95% CI, 36-83%; I² = 14.6%). The pooled 3-year PFS was 33% (95% CI, 7-76%), with substantial heterogeneity (I² = 62.8%). The pooled incidence of adverse events was 41% (95% CI, 25-60%; I² = 0.0%). Sensitivity analyses confirmed the robustness of pooled estimates. The retrospective literature also supported the finding that LT can achieve meaningful long-term survival in carefully selected patients.
conclusionsIn carefully selected patients with CRLM, LT is associated with durable long-term survival and an acceptable safety profile, supporting further prospective evaluation and refinement of selection criteria.
Indexed as
Identifiers
42213206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.